Abstract: A security object management system may include a management module including a device processor and a non-transitory computer readable medium including instructions stored thereon, and executable by the processor, for performing the following steps: accessing a database having stored therein data regarding a plurality of security objects, wherein the data includes ownership data regarding the assignment of rights associated with the security objects; and receiving user input to certify the accuracy of data associated with at least one of the security objects; wherein the computer readable medium further includes instructions for, in response to a change in data associated with a security object, executing a write back function whereby the change in the data is stored in a database that is accessible by a third party having access rights exclusive of ownership and administrator rights of the security object in the database.

Abstract: A security object management system may include a management module including a device processor and a non-transitory computer readable medium including instructions stored thereon, and executable by the processor, for performing the following steps: accessing a database having stored therein data regarding a plurality of security objects, wherein the data includes ownership data regarding the assignment of rights associated with the security objects; and receiving user input to change the reassignment of rights of at least one of the security objects from one user to another user of the system.

Abstract: Methods of producing populations of predominantly astrocytes, neurons or oligodendrocytes are provided. In addition, methods of treating mammals having astroglial tumors, oligodendrocyte tumors, or neuronal tumors are provided.

Abstract: The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression.

Abstract: This disclosure describes a novel population of cerebellum-derived neural stem cells that can be isolated from the adult brain, expanded, and differentiated into neurons, astrocytes and oligodendrocytes. This disclosure also describes compositions and methods for producing oligodendrocytes. Oligodendrocytes can be produced in vitro (e.g., in culture) or in vivo (e.g., for therapy or in a non-human transgenic animal) using the compositions and methods described herein.

Abstract: Methods of producing populations of predominantly astrocytes, neurons or oligodendrocytes are provided. In addition, methods of treating mammals having astroglial tumors, oligodendrocyte tumors, or neuronal tumors are provided.

Abstract: The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression.

Abstract: The present invention provides methods of treating central nervous system disorders, such as mood disorders (e.g., depression) and neurodegenerative diseases using compounds of formula (I). The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of central nervous system disorders.

Abstract: Methods of producing populations of predominantly astrocytes, neurons or oligodendrocytes are provided. In addition, methods of treating mammals having astroglial tumors, oligodendrocyte tumors, or neuronal tumors are provided.

Abstract: This disclosure describes a novel population of cerebellum-derived neural stem cells that can be isolated from the adult brain, expanded, and differentiated into neurons, astrocytes and oligodendrocytes. This disclosure also describes compositions and methods for producing oligodendrocytes. Oligodendrocytes can be produced in vitro (e.g., in culture) or in vivo (e.g., for therapy or in a non-human transgenic animal) using the compositions and methods described herein.

Abstract: Methods of producing populations of predominantly astrocytes, neurons or oligodendrocytes are provided. In addition, methods of treating mammals having astroglial tumors, oligodendrocyte tumors, or neuronal tumors are provided.

Abstract: Methods to introduce genetic material, such as DNA, to embryos, are disclosed. In some embodiments, the method involves preparing the pregnant mother to receive the genetic material into a blood transport vessel which passes to the embryo, avoiding a maternal capillary bed and introducing the material under low pressure so as not to kill the pregnant animal. The effectiveness of the method is such that the nucleic acid has been expressed in all the cells of the embryo and in the postnatal mouse, including the primordial germ cells, thus making the nucleic acid germ line heritable.

Abstract: The present invention provides methods of altering gene expression of embryos to provide compositions and methods for efficient generation of transgenic animals. In particular, the present invention provides compositions and methods for generating germline transgenic animals by direct injection of nucleic acid molecules into animals.

Abstract: Systems and methods for generating technical documents are provided. An exemplary embodiment of one such system includes a server computer system for generating technical documents having a database for storing information needed to generate technical documents, and a processor operable to cause the server computer system to allow multiple users to access the server computer system, input information needed to generate technical documents, and generate technical documents using the information input by the multiple users. An exemplary embodiment of one such method includes the steps of providing a server computer system operable to generate technical documents and allowing multiple users to access the server computer system, input information necessary for generating technical documents into the server computer system, and generate technical documents using the server computer system.

Abstract: The present invention provides methods of altering gene expression of embryos to provide compositions and methods for efficient generation of transgenic animals. In particular, the present invention provides compositions and methods for generating germ-line transgenic animals by direct injection of nucleic acid molecules into animals.

Abstract: The present invention provides methods of altering gene expression of embryos to provide compositions and methods for efficient generation of transgenic animals. In particular, the present invention provides compositions and methods for generating germ-line transgenic animals by direct injection of nucleic acid molecules into animals.

Abstract: Methods to introduce genetic material, such as DNA, to embryos, are disclosed. In some embodiments, the method involves preparing the pregnant mother to receive the genetic material into a blood transport vessel which passes to the embryo, avoiding a maternal capillary bed and introducing the material under low pressure so as not to kill the pregnant animal. The effectiveness of the method is such that the nucleic acid has been expressed in all the cells of the embryo and in the postnatal mouse, including the primordial germ cells, thus making the nucleic acid germ line heritable.

Abstract: Disclosed are methods and compositions for the diagnosis and treatment of diseases associated with aberrant expression of a somatostatin receptor (e.g., cancer) or with increased production of a factor regulatable by somatostatin (e.g., acromegaly). The compounds of the invention are of the general formulae: ##STR1## wherein P is a somatostatin peptide analog which binds to a somatostatin receptor,Y is D-tyrosine, L-tyrosine, or desamino-tyrosine,n is an integer from 1 to 32, inclusive,each q, independently, is an integer from 1 to 32, inclusive, and each s, independently, is an integer from 1 to 32, inclusive, where q and s can be the same or different, andX is of the formulaD--NH.sub.2 --CH(CH.sub.2).sub.m NH.sub.2 --CO.sub.2 H orL--NH.sub.2 --CH(CH.sub.2).sub.m NH.sub.2 --CO.sub.2 H,wherein m is an integer from 1 to 10, inclusive.

Abstract: Broadly, the present invention is directed to a method for the detection and differentiation of neoplastic tissue in a patient suspected of having neoplastic tissue. The method includes the administration of a radiolabeled somatostatin congener to the patient and accessing the patient with a radiation detection probe for determining tissue exhibiting elevated levels of radiation, viz., neoplastic tissue. However, before subjecting the patient to such administration, an initial determination preferably is made as to whether the radiolabeled somatostatin congener will bind to the tumor site, i.e., whether somatostatin receptors are associated with the neoplastic tissue. This is conveniently done with a wide variety of endocrine tumors, which release peptides or hormones, referred to as "biochemical markers. " In order to make this determination, initially a biochemical marker-inhibiting dose of unlabeled somatostatin congener is administered to the patient.